Xencor, Inc. (NASDAQ:XNCR) is set to post its quarterly earnings results after the market closes on Monday, July 31st. Analysts expect Xencor to post earnings of ($0.28) per share for the quarter.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.06. The company had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a return on equity of 5.98% and a net margin of 18.19%. On average, analysts expect Xencor to post $-1.220 EPS for the current fiscal year and $-1.660 EPS for the next fiscal year.
Xencor, Inc. (NASDAQ XNCR) opened at 23.665 on Friday. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The firm has a market capitalization of $1.11 billion, a PE ratio of 67.040 and a beta of 2.13. The firm’s 50-day moving average is $22.21 and its 200-day moving average is $23.17.
Several equities research analysts have commented on the stock. Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Xencor in a research report on Friday, June 16th. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Xencor presently has a consensus rating of “Buy” and an average price target of $28.67.
In related news, Director Bruce L. A. Carter sold 20,000 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $20.61, for a total value of $412,200.00. Following the sale, the director now directly owns 48,880 shares in the company, valued at approximately $1,007,416.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Edgardo Baracchini, Jr. sold 10,568 shares of the business’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total transaction of $274,873.68. Following the completion of the sale, the insider now owns 9,818 shares in the company, valued at $255,366.18. The disclosure for this sale can be found here. Insiders sold a total of 45,334 shares of company stock worth $1,014,282 over the last quarter. Insiders own 4.03% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.